Thompson J R, Douglas C M, Li W, Jue C K, Pramanik B, Yuan X, Rude T H, Toffaletti D L, Perfect J R, Kurtz M
Infectious Diseases, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
J Bacteriol. 1999 Jan;181(2):444-53. doi: 10.1128/JB.181.2.444-453.1999.
Cryptococcal meningitis is a fungal infection, caused by Cryptococcus neoformans, which is prevalent in immunocompromised patient populations. Treatment failures of this disease are emerging in the clinic, usually associated with long-term treatment with existing antifungal agents. The fungal cell wall is an attractive target for drug therapy because the syntheses of cell wall glucan and chitin are processes that are absent in mammalian cells. Echinocandins comprise a class of lipopeptide compounds known to inhibit 1,3-beta-glucan synthesis, and at least two compounds belonging to this class are currently in clinical trials as therapy for life-threatening fungal infections. Studies of Saccharomyces cerevisiae and Candida albicans mutants identify the membrane-spanning subunit of glucan synthase, encoded by the FKS genes, as the molecular target of echinocandins. In vitro, the echinocandins show potent antifungal activity against Candida and Aspergillus species but are much less potent against C. neoformans. In order to examine why C. neoformans cells are less susceptible to echinocandin treatment, we have cloned a homolog of S. cerevisiae FKS1 from C. neoformans. We have developed a generalized method to evaluate the essentiality of genes in Cryptococcus and applied it to the FKS1 gene. The method relies on homologous integrative transformation with a plasmid that can integrate in two orientations, only one of which will disrupt the target gene function. The results of this analysis suggest that the C. neoformans FKS1 gene is essential for viability. The C. neoformans FKS1 sequence is closely related to the FKS1 sequences from other fungal species and appears to be single copy in C. neoformans. Furthermore, amino acid residues known to be critical for echinocandin susceptibility in Saccharomyces are conserved in the C. neoformans FKS1 sequence.
新型隐球菌性脑膜炎是一种由新型隐球菌引起的真菌感染,在免疫功能低下的患者群体中较为常见。临床上这种疾病的治疗失败情况正在出现,通常与长期使用现有抗真菌药物治疗有关。真菌细胞壁是药物治疗的一个有吸引力的靶点,因为细胞壁葡聚糖和几丁质的合成过程在哺乳动物细胞中不存在。棘白菌素是一类已知可抑制1,3-β-葡聚糖合成的脂肽化合物,目前至少有两种属于该类别的化合物正在进行治疗危及生命的真菌感染的临床试验。对酿酒酵母和白色念珠菌突变体的研究确定,由FKS基因编码的葡聚糖合酶的跨膜亚基是棘白菌素的分子靶点。在体外,棘白菌素对念珠菌属和曲霉属菌种显示出强大的抗真菌活性,但对新型隐球菌的活性则低得多。为了研究为什么新型隐球菌细胞对棘白菌素治疗不太敏感,我们从新型隐球菌中克隆了酿酒酵母FKS1的同源物。我们开发了一种通用方法来评估新型隐球菌中基因的必需性,并将其应用于FKS1基因。该方法依赖于用一种可以以两种方向整合的质粒进行同源整合转化,其中只有一种方向会破坏目标基因的功能。分析结果表明,新型隐球菌FKS1基因对其生存能力至关重要。新型隐球菌FKS1序列与其他真菌物种的FKS1序列密切相关,并且在新型隐球菌中似乎是单拷贝的。此外,在酿酒酵母中已知对棘白菌素敏感性至关重要的氨基酸残基在新型隐球菌FKS1序列中是保守的。